CoChat
Sign Up
Cited by 361

The DOI matches its Crossref record.

Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models

Lu, Zhen, Zuo, Bingfeng, Jing, Renwei, Gao, Xianjun, Rao, Quan, Liu, Zhili, Qi, Han, Guo, Hongxing, Yin, HaiFang·2017·Journal of Hepatology
DOI 10.1016/j.jhep.2017.05.019
Open this paper in CoChat — free account

Abstract

Background & aims Dendritic cell (DC)-derived exosomes (DEXs) form a new class of vaccines for cancer immunotherapy. However, their potency in hepatocellular carcinoma (HCC), a life-threatening malignancy with limited treatment options in the clinic that responds poorly to immunotherapy, remains to be investigated. Methods Exosomes derived from α-fetoprotein (AFP)-expressing DCs (DEX AFP ) were investigated in three different HCC mouse models systemically. Tumor growth and microenvironment were monitored. Results DEX AFP elicited strong antigen-specific immune responses and resulted in significant tumor growth retardation and prolonged survival rates in mice with ectopic, orthotopic and carcinogen-induced HCC tumors that displayed antigenic and pathological heterogeneity. The tumor microenvironment was improved in DEX AFP -treated HCC mice, demonstrated by significantly more γ-interferon (IFN-γ)-expressing CD8 + T lymphocytes, elevated levels of IFN-γ and interleukin-2, and fewer CD25 + Foxp3 + regulatory T (Treg) cells and decreased levels of interleukin-10 and transforming growth factor-β in tumor sites. Lack of efficacy in athymic nude mice and CD8 + T cell-depleted mice showed that T cells contribute to DEX AFP -mediated antitumor function. Dynamic examination of the antitumor efficacy and the immune microenvironment in DEX AFP -treated orthotopic HCC mice at different time-points revealed a positive correlation between tumor suppression and immune microenvironment. Concl…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.05.019

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 27

  1. El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 · DOI
  2. Lin, 2012, Treatment of hepatocellular carcinoma: a systematic review, Liver Cancer, 1, 144, 10.1159/000343828 · DOI
  3. Lee, 2005, Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial, J Immunother, 28, 496, 10.1097/01.cji.0000171291.72039.e2 · DOI
  4. Chuma, 2015, New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions, Hepatol Res, 45, E1, 10.1111/hepr.12459 · DOI
  5. Palmer, 2009, A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma, Hepatology, 49, 124, 10.1002/hep.22626 · DOI
  6. Rao, 2016, Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and human in vitro, Hepatology, 64, 456, 10.1002/hep.28549 · DOI · Paper page
  7. Gould, 2013, As we wait: coping with an imperfect nomenclature for extracellular vesicles, J Extracell Vesicles, 2, 10.3402/jev.v2i0.20389 · DOI
  8. Lotvall, 2014, Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles, J Extracell Vesicles, 3, 26913, 10.3402/jev.v3.26913 · DOI · Paper page
  9. Pitt, 2014, Dendritic cell-derived exosomes as immunotherapies in the fight against cancer, J Immunol, 193, 1006, 10.4049/jimmunol.1400703 · DOI
  10. Zitvogel, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat Med, 4, 594, 10.1038/nm0598-594 · DOI
  11. Andre, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J Immunol, 172, 2126, 10.4049/jimmunol.172.4.2126 · DOI · Paper page
  12. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer, J Transl Med, 3, 9, 10.1186/1479-5876-3-9 · DOI
  13. Escudier, 2005, Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial, J Transl Med, 3, 10, 10.1186/1479-5876-3-10 · DOI
  14. Cany, 2011, AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice, J Hepatol, 54, 115, 10.1016/j.jhep.2010.06.027 · DOI
  15. Bradley, 1996, A direct role for IFN-gamma in regulation of Th1 cell development, J Immunol, 157, 1350, 10.4049/jimmunol.157.4.1350 · DOI
  16. Hong, 2014, Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma, Hepatology, 59, 1448, 10.1002/hep.26893 · DOI
  17. Qazi, 2009, Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism, Blood, 113, 2673, 10.1182/blood-2008-04-153536 · DOI
  18. Pardee, 2012, Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities, Oncoimmunology, 1, 48, 10.4161/onci.1.1.18344 · DOI
  19. Chew, 2012, Immune microenvironment in tumor progression: characteristics and challenges for therapy, J Oncol, 2012, 608406, 10.1155/2012/608406 · DOI
  20. Cordier, 1980, Development of thymus, parathyroids, and ultimo-branchial bodies in NMRI and nude mice, Am J Anat, 157, 227, 10.1002/aja.1001570303 · DOI
  21. Murugavel, 2008, Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies, Int J Infect Dis, 12, e71, 10.1016/j.ijid.2008.04.010 · DOI
  22. Shirakawa, 2009, Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer, Int J Oncol, 34, 649
  23. Liu, 2009, Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice, J Immunol, 182, 5960, 10.4049/jimmunol.0900008 · DOI
  24. Viaud, 2010, Dendritic cell-derived exosomes for cancer immunotherapy: what's next?, Cancer Res, 70, 1281, 10.1158/0008-5472.CAN-09-3276 · DOI
  25. Munich, 2012, Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands, Oncoimmunology, 1, 1074, 10.4161/onci.20897 · DOI
  26. Makarova-Rusher, 2015, The yin and yang of evasion and immune activation in HCC, J Hepatol, 62, 1420, 10.1016/j.jhep.2015.02.038 · DOI
  27. Butterfield, 2006, A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides, Clin Cancer Res, 12, 2817, 10.1158/1078-0432.CCR-05-2856 · DOI

Cited by

Sorted by citations

Metadata

Authors
Lu, Z., Zuo, B., Jing, R., Gao, X., Rao, Q., Liu, Z., Qi, H., Guo, H., & Yin, H.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2017-10
Volume
67
Issue
4
Pages
739-748
ISSN
0168-8278
DOI
10.1016/j.jhep.2017.05.019
Cited by
361
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review